Some early breast cancer after chemotherapy can be treated without surgery: New study

Thirty -seven patients with no evidence of residual cancer after chemotherapy for small, aggressive HER -2 positive or triple -negative tumors received radiation therapy, but no surgery was done.

Five years later, all 31 were still alive, due to no recurrence of cancer, researchers reported the annual meeting of the Society of Surgical Oncology 2025 in Tampa, Florida and JAMA Oncology.

Texas MD Anderson Cancer Center University Leader Dr. Henry Kuer said in a statement, “The absence of repetition of breast cancer on the five-year mark highlights the tremendous ability of this surgery-free approach to breast cancer management.”

He credits success for the use of a particularly accurate biopsy method to examine residual disease. During the image-directed vacuum assisted biopsy, his team used ultrasound or magnetic resonance imaging to obtain more accurate needle placements and collect several tissue samples with a single insertion.

Researchers have expanded the test to include more women, Kuer said.

“These released promising results suggest that eliminating breast surgery for aggressive breast cancer can become a new standard of care, which gives women an opportunity to preserve their body,” he said.

“While we hope that this approach will be regular, further clinical tests are necessary before it is a standard therapy.”

Small experimental pacemakers dissolve after use

Researchers reported that researchers reported in nature stated that an experimental cardiac pacemaker can be poured with a syringe and can be activated by light, and it dissolves when it is not needed, the researchers explained in nature.

Although it can work with the hearts of all sizes, pacemakers are well suited for small hearts of newborns, especially with congenital heart defects.

Pacing is controlled by a small, soft, flexible, wireless, wearable equipment on the patient’s chest. When the device detects an irregular heartbeat, it automatically shines a light pulse through the patient’s skin, breast and muscles to activate the pacemaker.

Designed for patients that require only temporary pacing, pacemaker contains biochapatable components that naturally dissolve in body fluids.

Researchers have so far tested the device in human hearts from large and small animals and deceased organ donors.

Infants undergoing surgery for congenital heart defects require only seven days of pacemaker, until the heart is cured, the leader of the Northwestern University, Igor Iffimov, Illinois mentioned in a statement.

“But they are seven days absolutely important,” said Ephimov.

Finally, he said that there is hope, “We can place this small pacemaker on a child’s heart and stimulate it with a soft, gentle, wearable tool. And no additional surgery is necessary to remove it.”

There is no benefit from the widely used stroke-primary device in the test

Researchers reported in the American College of Cardiology annual scientific session in Chicago that a widely used tool to protect from stroke after minimally invasive heart valve replacement procedures after failing to show any benefit in a large clinical test.

The device – Boston Scientific from Boston Scientific is designed to filter the tissue pieces, which can be released in the bloodstream when the doctors put a new heart valve through a artery in the hand, in a procedure, in a process, in a process called transcattering aortic valve replacement, or tavr.

If these embolism pieces are not caught, they can travel to the brain and cause stroke.

But TAVR was treated by TAVR between 7,635 UK patients at an average age of 81, after this process there was no difference in the stroke rate in 72 hours, even if the participants were randomized to pass through TAVR or without such protection, researchers found.

The rate of stroke in the sentinel group was 2.1% and 2.2% in the control group.

According to a report of the test published in the New England Journal of Medicine, there was no difference between groups in any reason, severity of stroke, stroke and disabled of cognitive results.

Researchers stated that Sentinel is the most frequently used embolic protection device in TAVR processes.

The Leader of the University of Oxford University, Dr. Rajesh Kharband said that the test was quite large and was appropriately designed to address the question whether the watchdog cerebral security system is effective in these patients.

“Our study provides evidence that there is no value in regular use of this device during (TAVR),” he said.

Boston Scientific told Reuters that an upcoming analysis of 10,000 patients with similar results to be presented at a medical meeting next month and earlier testing with similar results can help identify the subgroups of patients who can benefit from the guards.